Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI watchdog aims to catch doctor errors in High-Stakes care

NCT ID NCT07597499

Knowledge-focused Sponsor: Waymark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study tests a new AI tool called ANCHOR that acts like a safety checker for doctors treating very sick patients. 240 adults in Ohio, Washington, and Virginia will be randomly assigned to standard care, AI-assisted care, or AI-assisted care plus ANCHOR. The goal is to see if ANCHOR helps reduce mistakes like missed diagnoses or wrong medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

240 people

The number who actually took part.

Started

May 2026

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA: 1. Age 18 years or older. 2. Attributed to a participating Waymark provider (academic medical center, community-hospital network, federally qualified health center, or independent physician practice in Ohio, Washington, or Virginia; full TIN-consolidated list deposited at the Open Science Framework). 3. Meets high-risk multidisciplinary criteria (combined claims-based and clinical: 2 or more emergency-department visits or 1 or more hospitalization in the prior 12 months, 5 or more active medications, 2 or more active specialist relationships, 2 or more chronic conditions, or claims-based equivalents). 4. Encounter occurs in one of the three Waymark service modalities: high-risk primary care, specialty care coordination, or real-time telemedicine urgent care. 5. English-language clinical documentation. 6. Encounter requires clinical reasoning (not administrative-only). EXCLUSION CRITERIA: 1. Pediatric (age less than 18 years). 2. Hospice or palliative-care-exclusive care plan. 3. Active psychiatric crisis routed to crisis line. 4. Encounter is administrative only. 5. Pharmacy-only encounter that does not surface a clinical decision to the supervising physician. 6. Encounter where the supervising physician is the principal investigator. 7. Patient enrolled in a competing AI-safety study within the prior 90 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial intelligence-assisted care are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial intelligence-assisted care Clinical decision support High-risk multidisciplinary care Telemedicine

Contacts and locations

Locations

  • Waymark

    San Francisco, California, 94115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.